A dedicated focus on product research and development (R&D) and operational excellence ensures we are well positioned to deliver new and improved therapies for unmet need. For CSL, R&D is a critical driver of sustainability.
The CSL R&D Governance framework (as illustrated) is a system of committees and employees with clearly allocated decisionmaking rights and defined remits, designed to ensure that R&D effectively supports the delivery of CSL strategic objectives. The framework is designed to allow high quality, timely decision making for individual projects and the global R&D portfolio.
Strategic direction, portfolio decisions, prioritisation and resource allocation are governed by the CSL Board, Strategic Leadership Group (SLG) and PharmaPlan Committee (PPC). The PPC is the peak governance body within R&D and manages portfolio investment and execution in line with the guidance provided by the SLG and the Innovation and Development Committeeof the Board. The PPC is composed of senior stakeholders from across R&D, Finance, Operations and Commercial and is chaired by the Chief Scientific Officer (CSO). The PPC is supported by the Research Portfolio Management Committee (RPMC), Project Review Committees (PRCs) and the Global Life Cycle Management Review Board (GLRB). These committees are cross-functional with representatives from across CSL sites. The focus of these committees is to review, monitor and give guidance on and endorse R&D projects progressing from research to development through to lifecycle management respectively.
Core Project Teams (CPT) execute the projects. These teams are headed by the Project Sponsor and Project Manager and have experts from each of the functions. CPTs ensure that the projects deliver to scope, budget and timelines in line with the project objectives. Each of the underlying expert teams focus on how to deliver on their respective remits.
Our research projects are undertaken globally with research teams drawing together employees from different countries depending on their expertise. We have developed a global project management framework to facilitate collaboration across national and cultural boundaries and to harness the strength of our diversity.
We establish strategic partnerships with academic and other organisations globally to complement our in - house expertise. These collaborative partnerships support a range of programs including early - stage research and later stage development in plasma therapies, vaccines, and recombinant products.A range of advisers provide additional strategic insights into our product development initiatives.
We enter into collaborative agreements with third parties to further the science and prospects for successful product development.These partnerships often result in shared knowledge, intellectual property or products.The collaboration agreements address issues such as research funding, payment of milestones achieved and royalties.Where possible, we undertake activities at our laboratories and those of our collaborators, to facilitate growth of expertise and cross - fertilisation of ideas.
Responsible research practices
CSL is committed to conducting all of its R&D activities in a responsible manner. This means complying with government regulations in all countries in which we conduct research and meeting industry codes and standards of best practice.
This approach ensures the quality of our research and protects the rights, safety and wellbeing of our clinical trial participants.It also ensures the close monitoring of animal welfare during animal - based studies.In addition we recognise our responsibility to be transparent about the results of our clinical trials, and to provide public positions in relation to the bioethical concerns of our stakeholders.
For more on our approach to clinical trials, the use of animals in research and other bio - ethical issues,
click here >>